Business
While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year.
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Aktis Oncology launched today with significant financing in hand to advance a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company’s launch was supported by pharma giants including Bristol Myers Squibb and Novartis.
The U.S. Attorney’s Office for Massachusetts charged Ishtiaq Ali Saaem, 37, with obstruction of justice for lying about his attempts to acquire 100 castor bean packets in order to develop the bioterror poison ricin. The acquisition was not recent, it took place on June 24, 2015.
In recent years, AI-fueled drug discovery programs have risen dramatically, particularly in regard to rare diseases.
Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
Another bluebird bio executive is jumping ship. Chief Medical Officer David Davidson is leaving the company on April 16.
BioSpace recently spoke with Sanjeev Luther, CEO and board member of Rafael Pharmaceuticals, a clinical-late stage metabolic therapeutics company.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
German shepherds take down bad guys, dalmatians pull people from fires, beagles sniff out bombs and now llamas fight COVID-19.
Five months after Be Biopharma launched with $52 million in Series A financing, the company tapped bluebird bio veteran Joanne Smith-Farrell as its new chief executive officer.